Genotype- and Phenotype-Guided Management of Congenital Long QT Syndrome

Current Problems in Cardiology

Volumn 38, Issue 10, 2013, Pages 417-455

  Giudicessi, John R ^a   Ackerman, Michael J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACCESSORY PROTEIN BETA SUBUNIT; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANKYRIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALMODULIN; DELAYED RECTIFIER POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; ION CHANNEL; ION CHANNEL PORE FORMING ALPHA SUBUNIT; METOPROLOL; MEXILETINE; NADOLOL; POTASSIUM; POTASSIUM CHANNEL; POTASSIUM CHANNEL KCNE1; POTASSIUM CHANNEL KCNQ1; PROPRANOLOL; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; UNCLASSIFIED DRUG;

AKAP9 GENE; ANDERSEN SYNDROME; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CALCIUM TRANSPORT; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR PROSTHESIS AND IMPLANT; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY MONITORING; EXERCISE TEST; FAINTNESS; GAIN OF FUNCTION MUTATION; GENE; GENE IDENTIFICATION; GENE LOCUS; GENE MUTATION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC LINKAGE; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE PHENOTYPE CORRELATION; GENOTYPING TECHNIQUE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FUNCTION; HEART MUSCLE POTENTIAL; HEART RATE; HEART REPOLARIZATION; HEART SURGERY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HERITABILITY; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KCNE1 GENE; KCNH2 GENE; KCNQ1 GENE; LONG QT SYNDROME; LONG QT SYNDROME 1; LONG QT SYNDROME 2; LONG QT SYNDROME 3; LOSS OF FUNCTION MUTATION; MOLECULAR DIAGNOSIS; MOLECULAR MECHANICS; MONOTHERAPY; MUTATIONAL ANALYSIS; PATHOGENESIS; PERCEPTION DEAFNESS; PHENOTYPE; POTASSIUM BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROVOCATION TEST; QT INTERVAL; QT PROLONGATION; QUALITY OF LIFE; RISK ASSESSMENT; RNA TRANSLATION; SCN5A GENE; SEIZURE; SINUS NODE DISEASE; SUDDEN CARDIAC DEATH; SYMPATHETIC TONE; TORSADE DES POINTES; TREATMENT OUTCOME;

ALGORITHMS; ELECTROCARDIOGRAPHY; EVIDENCE-BASED MEDICINE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HUMANS; LONG QT SYNDROME; MUTATION; PHENOTYPE; RISK ASSESSMENT;

EID: 84884804986     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2013.08.001     Document Type: Article

References (132)

1. Moss A.J., Long Q.T. Syndrome. J Am Med Assoc 2003, 289:2041-2044.
2. Schwartz P.J., Crotti L., Insolia R. Long-QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol 2012, 5:868-877.
3. Romano C., Gemme G., Pongiglione R. Rare cardiac arrythmias of the pediatric age. II. Syncopal attacks due to paroxysmal ventricular fibrillation. Clin Pediatr 1963, 45:656-683. [Presentation of 1st Case in Italian Pediatric Literature].
4. Ward O.C.A. New familial cardiac syndrome in children. J Ir Med Assoc 1964, 54:103-106.
5. Schwartz P.J., Stramba-Badiale M., Crotti L., et al. Prevalence of the congenital long-QT syndrome. Circulation 2009, 120:1761-1767.
6. Jervell A., Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957, 54:59-68.
7. Fraser G.R., Froggatt P., Murphy T. Genetical aspects of the cardio-auditory syndrome of Jervell and Lange-Nielsen (Congenital deafness and electrocardiographic abnormalities). Ann Hum Genet 1964, 28:133-157.
8. Splawski I., Timothy K.W., Sharpe L.M., et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004, 119:19-31.
9. Giudicessi J.R., Ackerman M.J. Determinants of incomplete penetrance and variable expressivity in heritable cardiac arrhythmia syndromes. Transl Res 2013, 161:1-14.
10. Zheng Z.J., Croft J.B., Giles W.H., Mensah G.A. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001, 104:2158-2163.
11. Fishman G.I., Chugh S.S., Dimarco J.P., et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 2010, 122:2335-2348.
12. Nerbonne J.M., Kass R.S. Molecular physiology of cardiac repolarization. Physiol Rev 2005, 85:1205-1253.
13. Giudicessi J.R., Ackerman M.J. Potassium-channel mutations and cardiac arrhythmias-diagnosis and therapy. Nat Rev Cardiol 2012, 9:319-332.
14. Morita H., Wu J., Zipes D.P. The QT syndromes: long and short. Lancet 2008, 372:750-763.
15. Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. Am J Physiol Heart Circ Physiol 2007, 293:H2024-H2038.
16. Wang Q., Curran M.E., Splawski I., et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996, 12:17-23.
17. Curran M.E., Splawski I., Timothy K.W., Vincent G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80:795-803.
18. Wang Q., Shen J., Splawski I., et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995, 80:805-811.
19. Splawski I., Shen J., Timothy K.W., et al. Spectrum of mutations in long-QT syndrome genes KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000, 102:1178-1185.
20. Tester D.J., Will M.L., Haglund C.M., Ackerman M.J. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm 2005, 2:507-517.
21. Sanguinetti M.C., Curran M.E., Zou A., et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996, 384:80-83.
22. Wangemann P. Supporting sensory transduction: cochlear fluid homeostasis and the endocochlear potential. J Physiol 2006, 576:11-21.
23. Schwartz P.J., Priori S.G., Spazzolini C., et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001, 103:89-95.
24. Splawski I., Timothy K.W., Vincent G.M., Atkinson D.L., Keating M.T. Molecular basis of the long-QT syndrome associated with deafness. N Engl J Med 1997, 336:1562-1567.
25. Giudicessi J.R., Ackerman M.J. Prevalence and potential genetic determinants of sensorineural deafness in KCNQ1 homozygosity and compound heterozygosity. Circ Cardiovasc Genet 2013, 6:193-200.
26. Schwartz P.J., Priori S.G., Napolitano C. How really rare are rare diseases?: the intriguing case of independent compound mutations in the long QT syndrome. J Cardiovasc Electrophysiol 2003, 14:1120-1121.
27. Westenskow P., Splawski I., Timothy K.W., Keating M.T., Sanguinetti M.C. Compound mutations: a common cause of severe long-QT syndrome. Circulation 2004, 109:1834-1841.
28. Itoh H., Shimizu W., Hayashi K., et al. Long QT syndrome with compound mutations is associated with a more severe phenotype: a Japanese multicenter study. Heart Rhythm 2010, 7:1411-1418.
29. Kannankeril P., Roden D.M., Darbar D. Drug-induced long QT syndrome. Pharmacol Rev 2010, 62:760-781.
30. Bennett P.B., Yazawa K., Makita N., George A.L. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995, 376:683-685.
31. Ruan Y., Liu N., Priori S.G. Sodium channel mutations and arrhythmias. Nat Rev Cardiol 2009, 6:337-348.
32. + channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995, 92:3381-3386.
33. Stramba-Badiale M., Priori S.G., Napolitano C., et al. Gene-specific differences in the circadian variation of ventricular repolarization in the long QT syndrome: a key to sudden death during sleep?. Ital Heart J 2000, 1:323-328.
34. Jeyaraj D., Haldar S.M., Wan X., et al. Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature 2012, 483:96-99.
35. Barhanin J., Lesage F., Guillemare E., Fink M., Lazdunski M., Romey G. K(V) LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature 1996, 384:78-80.
36. + current by protein kinase C and protein kinase A. Circ Res 1998, 83:995-1002.
37. Splawski I., Tristani-Firouzi M., Lehmann M.H., Sanguinetti M.C., Keating M.T. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet 1997, 17:338-340.
38. Chen L., Marquardt M.L., Tester D.J., Sampson K.J., Ackerman M.J., Kass R.S. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci U S A 2007, 104:20990-20995.
39. Duggal P., Vesely M.R., Wattanasirichaigoon D., Villafane J., Kaushik V., Beggs A.H. Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of long-QT syndrome. Circulation 1998, 97:142-146.
40. Abbott G.W., Sesti F., Splawski I., et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999, 97:175-187.
41. Weerapura M., Nattel S., Chartier D., Caballero R., Hebert T.E. A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?. J Physiol 2002, 540:15-27.
42. Pourrier M., Zicha S., Ehrlich J., Han W., Nattel S. Canine ventricular KCNE2 expression resides predominantly in Purkinje fibers. Circ Res 2003, 93:189-191.
43. Jiang M., Zhang M., Tang D.G., et al. KCNE2 protein is expressed in ventricles of different species, and changes in its expression contribute to electrical remodeling in diseased hearts. Circulation 2004, 109:1783-1788.
44. + channel gating: a mechanism for pro-arrhythmia in long QT syndrome type 6. J Physiol 2003, 551:253-262.
45. Vatta M., Ackerman M.J., Ye B., et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006, 114:2104-2112.
46. Medeiros-Domingo A., Kaku T., Tester D.J., et al. SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 2007, 116:134-142.
47. Ueda K., Valdivia C., Medeiros-Domingo A., et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci U S A 2008, 105:9355-9360.
48. Yang Y., Liang B., Liu J., et al. Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet 2010 Jun 11, 86:872-880.
49. Beckmann C., Rinne A., Littwitz C., et al. G protein-activated (GIRK) current in rat ventricular myocytes is masked by constitutive inward rectifier current (I(K1)). Cell Physiol Biochem 2008, 21:259-268.
50. Schott J.J., Charpentier F., Peltier S., et al. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995, 57:1114-1122.
51. Mohler P.J., Schott J.J., Gramolini A.O., et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003, 421:634-639.
52. Mohler P.J., Splawski I., Napolitano C., et al. A cardiac arrhythmia syndrome caused by loss of ankyrin-B function. Proc Natl Acad Sci U S A 2004, 101:9137-9142.
53. Mohler P.J., Le Scouarnec S., Denjoy I., et al. Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation 2007, 115:432-441.
54. Andersen E.D., Krasilnikoff P.A., Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome?. Acta Paediatr Scand 1971, 60:559-564.
55. Tawil R., Ptacek L.J., Pavlakis S.G., et al. Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol 1994, 35:326-330.
56. Plaster N.M., Tawil R., Tristani-Firouzi M., et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell 2001, 105:511-519.
57. Tristani-Firouzi M., Jensen J.L., Donaldson M.R., et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002, 110:381-388.
58. Zhang L., Benson D.W., Tristani-Firouzi M., et al. Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotype. Circulation 2005, 111:2720-2726.
59. Barrett C.F., Tsien R.W. The Timothy syndrome mutation differentially affects voltage- and calcium-dependent inactivation of CaV1.2 L-type calcium channels. Proc Natl Acad Sci U S A 2008, 105:2157-2162.
60. Splawski I., Timothy K.W., Decher N., et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci U S A 2005, 102:8089-8096. [discussion 6-8].
61. Etheridge S.P., Bowles N.E., Arrington C.B., et al. Somatic mosaicism contributes to phenotypic variation in Timothy syndrome. Am J Med Genet A 2011, 155A:2578-2583.
62. Dufendach K.A., Giudicessi J.R., Boczek N.J., Ackerman MJ. Maternal mosaicsim confounds the neonatal diagnosis of type 1 Timothy syndrome. Pediatrics 2013 Jun, 131:e1991-e1995. Epub 2013 May 20. 10.1542/peds.2012-2941.
63. Crotti L., Johnson C.N., Graf E., et al. Calmodulin mutations associated with recurrent cardiac arrest in infants. Circulation 2013 Mar 5, 127:1009-1017. Epub 2013 Feb 6. 10.1161/CIRCULATIONAHA.112.001216.
64. Lahtinen A.M., Marjamaa A., Swan H., Kontula K. KCNE1 D85N polymorphism-a sex-specific modifier in type 1 long QT syndrome?. BMC Med Genet 2011, 12:11.
65. Crotti L., Lundquist A.L., Insolia R., et al. KCNH2-K897T is a genetic modifier of latent congenital long-QT syndrome. Circulation 2005, 112:1251-1258.
66. Makielski J.C., Ye B., Valdivia C.R., et al. A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ Res 2003, 93:821-828.
67. Viswanathan P.C., Benson D.W., Balser J.R. A common SCN5A polymorphism modulates the biophysical effects of an SCN5A mutation. J Clin Invest 2003, 111:341-346.
68. Amin A.S., Giudicessi J.R., Tijsen A.J., et al. Variants in the 3' untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner. Eur Heart J 2012, 33:714-723.
69. Park J.K., Martin L.J., Zhang X., Jegga A.G., Benson D.W. Genetic variants in SCN5A promoter are associated with arrhythmia phenotype severity in patients with heterozygous loss-of-function mutation. Heart Rhythm 2012, 9:1090-1096.
70. Hein L., Altman J.D., Kobilka B.K. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999, 402:181-184.
71. Mason D.A., Moore J.D., Green S.A., Liggett S.B. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999, 274:12670-12674.
72. Paavonen K.J., Swan H., Piippo K., et al. Beta1-adrenergic receptor polymorphisms, QTc interval and occurrence of symptoms in type 1 of long QT syndrome. Int J Cardiol 2007, 118:197-202.
73. Schwartz P.J., Vanoli E., Crotti L., et al. Neural control of heart rate is an arrhythmia risk modifier in long QT syndrome. J Am Coll Cardiol 2008, 51:920-929.
74. Crotti L., Monti M.C., Insolia R., et al. NOS1AP is a genetic modifier of the long-QT syndrome. Circulation 2009, 120:1657-1663.
75. Tomas M., Napolitano C., De Giuli L., et al. Polymorphisms in the NOS1AP gene modulate QT interval duration and risk of arrhythmias in the long QT syndrome. J Am Coll Cardiol 2010, 55:2745-2752.
76. Refsgaard L., Holst A.G., Sadjadieh G., Haunso S., Nielsen J.B., Olesen M.S. High prevalence of genetic variants previously associated with LQT syndrome in new exome data. Eur J Hum Genet 2012 Aug, 20:905-908. Epub 2012 Feb 29. 10.1038/ejhg.2012.23.
77. Priori S.G., Napolitano C., Schwartz P.J. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999, 99:529-533.
78. Tester D.J., Will M.L., Haglund C.M., Ackerman M.J. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol 2006, 47:764-768.
79. Moss A.J., Zareba W., Benhorin J., et al. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation 1995, 92:2929-2934.
80. Zhang L., Timothy K.W., Vincent G.M., et al. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation 2000, 102:2849-2855.
81. Schwartz P.J., Malliani A. Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. Am Heart J 1975, 89:45-50.
82. Taggart N.W., Haglund C.M., Tester D.J., Ackerman M.J. Diagnostic miscues in congenital long-QT syndrome. Circulation 2007, 115:2613-2620.
83. Hermosillo A.G., Falcon J.C., Marquez M.F., Arteaga D., Cardenas M. Positive head-up tilt table test in patients with the long QT syndrome. Europace 1999, 1:213-217.
84. Colman N., Bakker A., Linzer M., Reitsma J.B., Wieling W., Wilde A.A. Value of history-taking in syncope patients: in whom to suspect long QT syndrome?. Europace 2009, 11:937-943.
85. Rautaharju P.M., Surawicz B., Gettes L.S., et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 2009, 119:e241-e250.
86. Schwartz P.J., Moss A.J., Vincent G.M., Crampton R.S. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993, 88:782-784.
87. Schwartz P.J., Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation 2011, 124:2181-2184.
88. Priori S.G., Schwartz P.J., Napolitano C., et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003, 348:1866-1874.
89. Ackerman M.J., Khositseth A., Tester D.J., Hejlik J.B., Shen W.K., Porter C.B. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002, 77:413-421.
90. Wong J.A., Gula L.J., Klein G.J., Yee R., Skanes A.C., Krahn A.D. Utility of treadmill testing in identification and genotype prediction in long-QT syndrome. Circ Arrhythm Electrophysiol 2010, 3:120-125.
91. Kapa S., Tester D.J., Salisbury B.A., et al. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation 2009, 120:1752-1760.
92. Ackerman M.J., Priori S.G., Willems S., et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011, 8:1308-1339.
93. Giudicessi J.R., Ackerman M.J. Genetic testing in heritable cardiac arrhythmia syndromes: differentiating pathogenic mutations from background genetic noise. Curr Opin Cardiol 2013, 28:63-71.
94. Giudicessi J.R., Kapplinger J.D., Tester D.J., et al. Phylogenetic and physicochemical analyses enhance the classification of rare nonsynonymous single nucleotide variants in type 1 and 2 long-QT syndrome. Circ Cardiovasc Genet 2012, 5:519-528.
95. Schwartz P.J., Spazzolini C., Crotti L., et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation 2006, 113:783-790.
96. Goldenberg I., Moss A.J., Zareba W., et al. Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome. J Cardiovasc Electrophysiol 2006, 17:1161-1168.
97. Sauer A.J., Moss A.J., McNitt S., et al. Long QT syndrome in adults. J Am Coll Cardiol 2007, 49:329-337.
98. Mullally J., Goldenberg I., Moss A.J., et al. Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations. Heart Rhythm 2013, 10:378-382.
99. Schwartz P.J., Periti M., Malliani A. The long Q-T syndrome. Am Heart J 1975, 89:378-390.
100. Schwartz P.J. Idiopathic long QT syndrome: progress and questions. Am Heart J 1985, 109:399-411.
101. Moss A.J., Zareba W., Hall W.J., et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000, 101:616-623.
102. Priori S.G., Napolitano C., Schwartz P.J., et al. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. J Am Med Assoc 2004, 292:1341-1344.
103. Villain E., Denjoy I., Lupoglazoff J.M., et al. Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome. Eur Heart J 2004, 25:1405-1411.
104. Shimizu W., Tanabe Y., Aiba T., et al. Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 2002, 39:1984-1991.
105. Chatrath R., Bell C.M., Ackerman M.J. Beta-blocker therapy failures in symptomatic probands with genotyped long-QT syndrome. Pediatr Cardiol 2004, 25:459-465.
106. Chockalingam P., Crotti L., Girardengo G., et al. Not all beta-blockers are equal in the management of long QT syndrome types 1 and 2: higher recurrence of events under metoprolol. J Am Coll Cardiol 2012, 60:2092-2099.
107. Odero A., Bozzani A., De Ferrari G.M., Schwartz P.J. Left cardiac sympathetic denervation for the prevention of life-threatening arrhythmias: the surgical supraclavicular approach to cervicothoracic sympathectomy. Heart Rhythm 2010, 7:1161-1165.
108. Atallah J., Fynn-Thompson F., Cecchin F., DiBardino D.J., Walsh E.P., Berul C.I. Video-assisted thoracoscopic cardiac denervation: a potential novel therapeutic option for children with intractable ventricular arrhythmias. Ann Thorac Surg 2008, 86:1620-1625.
109. Collura C.A., Johnson J.N., Moir C., Ackerman M.J. Left cardiac sympathetic denervation for the treatment of long QT syndrome and catecholaminergic polymorphic ventricular tachycardia using video-assisted thoracic surgery. Heart Rhythm 2009, 6:752-759.
110. Schwartz P.J., Snebold N.G., Brown A.M. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. Am J Cardiol 1976, 37:1034-1040.
111. Schwartz P.J., Priori S.G., Cerrone M., et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004, 109:1826-1833.
112. Hwang S.W., Thomas J.G., Whitehead W.E., et al. Left thorascopic sympathectomy for refractory long QT syndrome in children. J Neurosurg Pediatr 2011, 8:455-459.
113. Coleman M.A., Bos J.M., Johnson J.N., et al. Videoscopic left cardiac sympathetic denervation for patients with recurrent ventricular fibrillation/malignant ventricular arrhythmia syndromes besides congenital long-QT syndrome. Circ Arrhythm Electrophysiol 2012, 5:782-788.
114. Schwartz P.J., Spazzolini C., Priori S.G., et al. Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?: data from the European Long-QT Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. Circulation 2010, 122:1272-1282.
115. Horner J.M., Kinoshita M., Webster T.L., Haglund C.M., Friedman P.A., Ackerman M.J. Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience. Heart Rhythm 2010, 7:1616-1622.
116. Vincent G.M., Schwartz P.J., Denjoy I., et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures". Circulation 2009, 119:215-221.
117. Ackerman M.J., Tester D.J., Porter C.J. Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc 1999, 74:1088-1094.
118. Zipes D.P., Ackerman M.J., Estes N.A., Grant A.O., Myerburg R.J., Van Hare G. Task Force 7: arrhythmias. J Am Coll Cardiol 2005, 45:1354-1363.
119. Pelliccia A., Fagard R., Bjornstad H.H., et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005, 26:1422-1445.
120. Johnson J.N., Ackerman M.J. Competitive sports participation in athletes with congenital long QT syndrome. J Am Med Assoc 2012, 308:764-765.
121. Johnson J.N., Ackerman M.J. Return to play? Athletes with congenital long QT syndrome. Br J Sports Med 2013, 47:28-33.
122. Wilde A.A., Jongbloed R.J., Doevendans P.A., et al. Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol 1999, 33:327-332.
123. Rashba E.J., Zareba W., Moss A.J., et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS investigators. Circulation 1998, 97:451-456.
124. Khositseth A., Tester D.J., Will M.L., Bell C.M., Ackerman M.J. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm 2004, 1:60-64.
125. Moss A.J., Windle J.R., Hall W.J., et al. Safety and efficacy of flecainide in subjects with long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 2005, 10:59-66.
126. Ruan Y., Liu N., Bloise R., Napolitano C., Priori S.G. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients. Circulation 2007, 116:1137-1144.
127. Wang D.W., Crotti L., Shimizu W., et al. Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel. Circ Arrhythm Electrophysiol 2008, 1:370-378.
128. Priori S.G., Napolitano C., Schwartz P.J., Bloise R., Crotti L., Ronchetti E. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation 2000, 102:945-947.
129. Fredj S., Sampson K.J., Liu H., Kass R.S. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 2006, 148:16-24.
130. Moss A.J., Zareba W., Schwarz K.Q., Rosero S., McNitt S., Robinson J.L. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 2008, 19:1289-1293.
131. Goldenberg I., Horr S., Moss A.J., et al. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol 2011, 57:51-59.
132. Boczek N.J., Best J.M., Tester D.J., Giudicessi J.R., Middha S., Evans J.M., Kamp T.J., Ackerman M.J. Exome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, CACNA1C, linked to autosomal dominant long QT syndrome. Circ Cardiovasc Genet 2013 Jun, 6:279-289.